Compare Enveric Biosciences Inc (ENVB) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Prospect Capital Corporation — how do they compare? Enveric Biosciences Inc trades at $1.37 (market cap $5.32M), while Prospect Capital Corporation trades at $2.33 (market cap $1.14B). The key difference: Prospect Capital Corporation is far larger — about 214.3× Enveric Biosciences Inc's market cap, and Prospect Capital Corporation pays a 22.03% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | PSEC | |
|---|---|---|
Market Cap | $5.32M | $1.14B |
Sector | Health | Financials |
52-Week High | $17.40 | $3.47 |
52-Week Low | $1.28 | $2.15 |
Enterprise Value | $408.82K | — |
Dividend Yield | — | 22.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
PSEC trades at $2.295, up 1.1% today, with a neutral technical signal and bearish moving averages. The stock shows a low P/B of 0.39 but negative revenue and net income in 2025. Recent earnings beats and consistent dividends highlight income potential, though financial performance remains volatile with a -495.94% net income margin. News includes a new investment in ShipOffers and the sale of Valley Electric.
Outlook is mixed: deep discount to NAV and high yield appeal to income seekers, but persistent financial deterioration and analyst skepticism pose risks. Upside depends on portfolio stability and NAV recovery, while downside risks include further dividend cuts and economic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
